|
|
||||||||
Article |
Pharmacogenetics of Membrane Transporters Group, Department of Biopharmaceutical Sciences, University of California San Francisco
Category: Genotype
PharmGKB Submission Number: PS203001 http://www.pharmgkb.org/do/serve?objId=PA329&objCls=Gene
Date of Submission: June 16, 2003
Project: Pharmacogenetics of Membrane Transporters
HGNC Symbol: SLC22A1
HGNC Name: solute carrier family 22 (organic cation transporter), member 1
Synonym: SLC22A1
Gene Ontology Terms: GO:0005624 membrane fraction, GO:0005887 integral to plasma membrane, GO: 0006811 ion transport, GO:0015075 ion transporter activity, GO:0015101 organic cation transporter activity, GO:0015695 organic cation transport, GO:0016021 integral to membrane
Locus ID: 6580
GenBank Accession: AV684761, U77086, X98332
Pharmacogenetic Significance: Genetic variation in SLC22A1 may result in variation in hepatic absorption, therapeutic effects, and/or toxicities of its substrates.
Pharmacological Significance: SLC22A1 is predominately expressed in the liver and appears to play a role in hepatic absorption of hydrophilic organic cations of diverse chemical structure including many drugs such as metformin and cimetidine as well as the neurotoxin MPP+ (1-methyl-4-phenylpyridinium).
Potential Drug Interactions: clonidine, cimetidine, debrisoquine, ranitidine, metformin, phenformin, pindolol, procainamide
Functional Characteristics: SLC22A1 is a facilitated transporter found on the sinusoidal membrane of hepatocytes. The protein mediates the transport of small molecular weight hydrophilic organic cations from the extracellular fluids into the hepatocyte.
Summary of Data Submitted:
Publications:
First published on February 23, 2004
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |